Fluor wins $2 billion Novo contract to build API manufacturing facility
pharmafile | December 22, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Fluor, Novo Nordisk, north carolina
Fluor Corporation has won an engineering, procurement and construction management contract for Novo Nordisk’s $2 billion diabetes active pharmaceutical ingredient manufacturing facility based in Clayton, North Carolina.
The facility is expected to provide jobs to 2,500 craft employees and subcontractor jobs during construction. Once operational the facility will employ 700 people. The project is expected to be completed by mid-2019. The space will cover 830,000 square feet and will produce ingredients to be used in the production of diabetes medication.
“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work,” said Morten Nielsen, senior vice president, Novo Nordisk, and responsible for the construction of the new facility. “We look forward to continued strong cooperation for the success of this project.”
“Fluor is honoured to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business. “This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”
Ben Hargreaves
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
